Not currently recruiting at UCSF
Capivasertib + Palbociclib + Fulvestrant for HR+/HER2- Advanced Breast Cancer (CAPItello-292).
Locally Advanced (Inoperable) or Metastatic Breast Cancer Breast Neoplasms Fulvestrant Palbociclib Capivasertib Capivasertib Plus Palbociclib and Fulvestrant
Lead Scientist at UCSF
- Hope Rugo
Dr. Hope Rugo is a medical oncologist and hematologist specializing in breast cancer research and treatment. A Clinical Professor of Medicine, Dr. Rugo joined the Breast Care Center in 1999 after a decade of experience at UCSF in malignant hematology and bone marrow transplantation for a variety of diseases, including breast cancer.
- accepting new patients at some sites,
but this study is not currently recruiting here
- Start Date
- Completion Date
- Phase 3 research study
- Study Type
- Expecting 700 study participants
- Last Updated